Specification of Semaglutide
| CAS No. | 910463-68-2 | Molecular Weight | 4113.57754 |
| Molecular Formula | C187H291N45O59 | Storage Condition | -20℃ |
Appearance:
white freeze-dried powder.
Product Description：
Semaglutide is a long-acting analog of the human glucagon-like peptide-1 (GLP-1) receptor, an agonist of the human GLP-1 receptor, and is clinically useful for the treatment of type 2 diabetes and obesity.
Product Use：
Semaglutide is primarily used to treat type 2 diabetes and obesity. It works through a variety of mechanisms:
Hypoglycemic action: Lowering of blood sugar by stimulating insulin secretion and inhibiting glucagon secretion in a glucose-dependent manner.
Weight loss: Helps with weight loss by reducing food intake, delaying stomach emptying, and suppressing appetite.
Product use method
Injection: Given subcutaneously once weekly, usually in doses of 0.5 mg, 1 mg, or 2.4 mg.
Oral tablets: Starting at 3 mg once daily and gradually increasing to 7 mg or 14 mg.
Product effects and side effects:
Treatment effectiveness: Semaglutide significantly reduced hemoglobin A1C levels in patients with type 2 diabetes and helped with weight loss in clinical trials.
Side effects: Common side effects include nausea, vomiting, diarrhea, and constipation. Often, increasing the dose gradually after starting with a low dose can reduce these side effects.
Product history and development background
Development of Semaglutide began in 2016, has completed multiple clinical trials, and was approved by the U.S. Food and Drug Administration (FDA) for diabetes treatment in 2017. In 2021, it was approved by the FDA for the treatment of obesity.
English
Nederland
